KR19990022354A - 약물 전달용 역 플루오로카본 유제 조성물 - Google Patents

약물 전달용 역 플루오로카본 유제 조성물 Download PDF

Info

Publication number: KR19990022354A
Authority: KR; South Korea
Prior art keywords: emulsion; fluorocarbon; formulation; polar liquid; group
Prior art date: 1995-06-07

Application number

KR1019970708834A

Other languages

English (en)

Korean (ko)

Inventor

토마스 이. 타라라

제프리 지. 위어스

레오 에이. 트레비노

알렉세이 카발노프

루이스 에이. 델라마리

지나 엠. 호퍼

헬렌 엠. 란니

데이비드 에이치. 클라인

티모시 제이. 펠루라

Original Assignee

펠루라, 티모시, 제이

테오도르 디. 로쓰

얼라이언스 파마슈티칼 코포레이션

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-06-07

Filing date

1996-06-05

Publication date

1999-03-25

1996-06-05 Application filed by 펠루라, 티모시, 제이, 테오도르 디. 로쓰, 얼라이언스 파마슈티칼 코포레이션 filed Critical 펠루라, 티모시, 제이

1999-03-25 Publication of KR19990022354A publication Critical patent/KR19990022354A/ko

Links

239000000839 emulsion Substances 0.000 title claims abstract description 267
239000000203 mixture Substances 0.000 title claims abstract description 107
NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 title claims abstract description 62
230000002441 reversible effect Effects 0.000 title claims description 70
238000012377 drug delivery Methods 0.000 title description 4
239000012071 phase Substances 0.000 claims abstract description 107
239000004094 surface-active agent Substances 0.000 claims abstract description 96
239000007788 liquid Substances 0.000 claims abstract description 69
239000003814 drug Substances 0.000 claims abstract description 62
230000001225 therapeutic effect Effects 0.000 claims abstract description 37
239000000032 diagnostic agent Substances 0.000 claims abstract description 33
229940039227 diagnostic agent Drugs 0.000 claims abstract description 33
229940124597 therapeutic agent Drugs 0.000 claims abstract description 26
108090000623 proteins and genes Proteins 0.000 claims abstract description 18
239000004530 micro-emulsion Substances 0.000 claims abstract description 16
102000004169 proteins and genes Human genes 0.000 claims abstract description 16
238000000034 method Methods 0.000 claims description 75
238000009472 formulation Methods 0.000 claims description 73
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 55
MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 claims description 54
-1 Phosphatidyl ethylene glycol Chemical compound 0.000 claims description 35
239000003795 chemical substances by application Substances 0.000 claims description 32
239000007791 liquid phase Substances 0.000 claims description 27
239000001273 butane Substances 0.000 claims description 24
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 23
JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 23
150000003904 phospholipids Chemical group 0.000 claims description 22
239000004215 Carbon black (E152) Substances 0.000 claims description 21
239000006185 dispersion Substances 0.000 claims description 21
239000000654 additive Substances 0.000 claims description 20
150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 20
LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 16
230000002269 spontaneous effect Effects 0.000 claims description 16
150000001298 alcohols Chemical class 0.000 claims description 15
239000008344 egg yolk phospholipid Substances 0.000 claims description 14
229940068998 egg yolk phospholipid Drugs 0.000 claims description 14
108090000790 Enzymes Proteins 0.000 claims description 13
102000004190 Enzymes Human genes 0.000 claims description 13
239000003242 anti bacterial agent Substances 0.000 claims description 13
PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims description 12
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 12
229940088710 antibiotic agent Drugs 0.000 claims description 12
239000002246 antineoplastic agent Substances 0.000 claims description 11
ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims description 10
AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 10
229940088598 enzyme Drugs 0.000 claims description 10
150000002632 lipids Chemical class 0.000 claims description 10
210000004072 lung Anatomy 0.000 claims description 10
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 10
TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 9
ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 9
229940041181 antineoplastic drug Drugs 0.000 claims description 9
239000002327 cardiovascular agent Substances 0.000 claims description 9
229940125692 cardiovascular agent Drugs 0.000 claims description 9
239000003889 eye drop Substances 0.000 claims description 9
102000039446 nucleic acids Human genes 0.000 claims description 9
108020004707 nucleic acids Proteins 0.000 claims description 9
150000007523 nucleic acids Chemical class 0.000 claims description 9
239000002872 contrast media Substances 0.000 claims description 8
ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 claims description 8
230000001804 emulsifying effect Effects 0.000 claims description 8
230000000241 respiratory effect Effects 0.000 claims description 8
239000013603 viral vector Substances 0.000 claims description 8
YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims description 7
QSBINWBNXWAVAK-PSXMRANNSA-N PE-NMe(16:0/16:0) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCNC)OC(=O)CCCCCCCCCCCCCCC QSBINWBNXWAVAK-PSXMRANNSA-N 0.000 claims description 7
BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims description 7
JCABVIFDXFFRMT-DIPNUNPCSA-N [(2r)-1-[ethoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] octadec-9-enoate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC)OC(=O)CCCCCCCC=CCCCCCCCC JCABVIFDXFFRMT-DIPNUNPCSA-N 0.000 claims description 7
235000014113 dietary fatty acids Nutrition 0.000 claims description 7
PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 7
239000000194 fatty acid Substances 0.000 claims description 7
229930195729 fatty acid Natural products 0.000 claims description 7
150000004665 fatty acids Chemical class 0.000 claims description 7
229910052757 nitrogen Inorganic materials 0.000 claims description 7
239000008251 pharmaceutical emulsion Substances 0.000 claims description 7
229940031439 squalene Drugs 0.000 claims description 7
TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims description 7
229940124599 anti-inflammatory drug Drugs 0.000 claims description 6
230000003115 biocidal effect Effects 0.000 claims description 6
TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical class FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 claims description 6
230000000996 additive effect Effects 0.000 claims description 5
229940035674 anesthetics Drugs 0.000 claims description 5
OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 claims description 5
MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 claims description 5
229940012356 eye drops Drugs 0.000 claims description 5
239000003193 general anesthetic agent Substances 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims description 5
229920000570 polyether Polymers 0.000 claims description 5
150000003839 salts Chemical class 0.000 claims description 5
IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 claims description 5
229930182558 Sterol Natural products 0.000 claims description 4
230000003444 anaesthetic effect Effects 0.000 claims description 4
239000000872 buffer Substances 0.000 claims description 4
235000016709 nutrition Nutrition 0.000 claims description 4
UJMWVICAENGCRF-UHFFFAOYSA-N oxygen difluoride Chemical class FOF UJMWVICAENGCRF-UHFFFAOYSA-N 0.000 claims description 4
229920001223 polyethylene glycol Polymers 0.000 claims description 4
150000003432 sterols Chemical class 0.000 claims description 4
235000003702 sterols Nutrition 0.000 claims description 4
230000008961 swelling Effects 0.000 claims description 4
150000003626 triacylglycerols Chemical class 0.000 claims description 4
125000005360 alkyl sulfoxide group Chemical group 0.000 claims description 3
238000007918 intramuscular administration Methods 0.000 claims description 3
238000007912 intraperitoneal administration Methods 0.000 claims description 3
239000002736 nonionic surfactant Substances 0.000 claims description 3
239000003381 stabilizer Substances 0.000 claims description 3
238000007920 subcutaneous administration Methods 0.000 claims description 3
150000001335 aliphatic alkanes Chemical class 0.000 claims description 2
239000008342 pharmaceutical dispersion Substances 0.000 claims description 2
230000000699 topical effect Effects 0.000 claims description 2
108700005077 Viral Genes Proteins 0.000 claims 6
230000003110 anti-inflammatory effect Effects 0.000 claims 3
241000631130 Chrysophyllum argenteum Species 0.000 claims 1
239000002563 ionic surfactant Substances 0.000 claims 1
235000021281 monounsaturated fatty acids Nutrition 0.000 claims 1
239000008194 pharmaceutical composition Substances 0.000 claims 1
239000008346 aqueous phase Substances 0.000 abstract description 11
239000003153 chemical reaction reagent Substances 0.000 abstract description 8
229910052731 fluorine Inorganic materials 0.000 abstract description 6
239000011737 fluorine Substances 0.000 abstract description 6
YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 abstract description 4
238000002156 mixing Methods 0.000 abstract description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 62
239000003921 oil Substances 0.000 description 61
239000011780 sodium chloride Substances 0.000 description 33
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 28
229940079593 drug Drugs 0.000 description 26
239000002245 particle Substances 0.000 description 25
235000019441 ethanol Nutrition 0.000 description 22
238000004945 emulsification Methods 0.000 description 20
SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 18
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 17
239000001110 calcium chloride Substances 0.000 description 17
229910001628 calcium chloride Inorganic materials 0.000 description 17
230000000694 effects Effects 0.000 description 17
230000001965 increasing effect Effects 0.000 description 17
MWRBNPKJOOWZPW-NYVOMTAGSA-N 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-NYVOMTAGSA-N 0.000 description 16
TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 16
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 15
238000002347 injection Methods 0.000 description 15
239000007924 injection Substances 0.000 description 15
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 15
WTWWXOGTJWMJHI-UHFFFAOYSA-N perflubron Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br WTWWXOGTJWMJHI-UHFFFAOYSA-N 0.000 description 15
229930182566 Gentamicin Natural products 0.000 description 14
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 14
235000012000 cholesterol Nutrition 0.000 description 14
239000012153 distilled water Substances 0.000 description 14
238000002360 preparation method Methods 0.000 description 14
229960001217 perflubron Drugs 0.000 description 13
150000002430 hydrocarbons Chemical class 0.000 description 12
AFSHUZFNMVJNKX-LLWMBOQKSA-N 1,2-dioleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](CO)OC(=O)CCCCCCC\C=C/CCCCCCCC AFSHUZFNMVJNKX-LLWMBOQKSA-N 0.000 description 11
229930195733 hydrocarbon Natural products 0.000 description 11
239000002356 single layer Substances 0.000 description 11
RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 10
239000000460 chlorine Substances 0.000 description 10
238000009826 distribution Methods 0.000 description 10
RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 10
229940074096 monoolein Drugs 0.000 description 10
ZEUUPKVZFKBXPW-TWDWGCDDSA-N (2s,3r,4s,5s,6r)-4-amino-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,5s,6r)-3-amino-6-(aminomethyl)-5-hydroxyoxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol;sulfuric acid Chemical compound OS(O)(=O)=O.N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N ZEUUPKVZFKBXPW-TWDWGCDDSA-N 0.000 description 9
238000010790 dilution Methods 0.000 description 9
239000012895 dilution Substances 0.000 description 9
229960004477 tobramycin sulfate Drugs 0.000 description 9
235000013601 eggs Nutrition 0.000 description 8
230000012010 growth Effects 0.000 description 8
238000003921 particle size analysis Methods 0.000 description 8
239000000523 sample Substances 0.000 description 8
239000000126 substance Substances 0.000 description 7
230000015572 biosynthetic process Effects 0.000 description 6
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 6
238000004581 coalescence Methods 0.000 description 6
MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 6
239000003995 emulsifying agent Substances 0.000 description 6
238000011049 filling Methods 0.000 description 6
239000012528 membrane Substances 0.000 description 6
229960004624 perflexane Drugs 0.000 description 6
ZJIJAJXFLBMLCK-UHFFFAOYSA-N perfluorohexane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F ZJIJAJXFLBMLCK-UHFFFAOYSA-N 0.000 description 6
230000008569 process Effects 0.000 description 6
230000002685 pulmonary effect Effects 0.000 description 6
238000000527 sonication Methods 0.000 description 6
PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 6
239000003981 vehicle Substances 0.000 description 6
XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 5
RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 5
BAECOWNUKCLBPZ-HIUWNOOHSA-N Triolein Natural products O([C@H](OCC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC)C(=O)CCCCCCC/C=C\CCCCCCCC BAECOWNUKCLBPZ-HIUWNOOHSA-N 0.000 description 5
PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 5
125000004432 carbon atom Chemical group C* 0.000 description 5
210000004027 cell Anatomy 0.000 description 5
229960004316 cisplatin Drugs 0.000 description 5
IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethyl sulfoxide Natural products CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
150000002500 ions Chemical class 0.000 description 5
229940057917 medium chain triglycerides Drugs 0.000 description 5
229960000195 terbutaline Drugs 0.000 description 5
229940117972 triolein Drugs 0.000 description 5
238000009423 ventilation Methods 0.000 description 5
DRAWQKGUORNASA-CLFAGFIQSA-N 1,3-dioleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)COC(=O)CCCCCCC\C=C/CCCCCCCC DRAWQKGUORNASA-CLFAGFIQSA-N 0.000 description 4
YWMSSKBMOFPBDM-UHFFFAOYSA-N 4-carbamoylbenzenesulfonyl chloride Chemical compound NC(=O)C1=CC=C(S(Cl)(=O)=O)C=C1 YWMSSKBMOFPBDM-UHFFFAOYSA-N 0.000 description 4
DRAWQKGUORNASA-UHFFFAOYSA-N Anticancer Glycerol Ester PMV70P691-119 Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCC=CCCCCCCCC DRAWQKGUORNASA-UHFFFAOYSA-N 0.000 description 4
229960001656 amikacin sulfate Drugs 0.000 description 4
239000007864 aqueous solution Substances 0.000 description 4
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
230000008859 change Effects 0.000 description 4
DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 4
238000000354 decomposition reaction Methods 0.000 description 4
208000015181 infectious disease Diseases 0.000 description 4
229910052760 oxygen Inorganic materials 0.000 description 4
239000001301 oxygen Substances 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
239000000243 solution Substances 0.000 description 4
VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 3
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 3
102000002322 Egg Proteins Human genes 0.000 description 3
108010000912 Egg Proteins Proteins 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
239000004098 Tetracycline Substances 0.000 description 3
239000002253 acid Substances 0.000 description 3
239000013543 active substance Substances 0.000 description 3
229940126575 aminoglycoside Drugs 0.000 description 3
230000000844 anti-bacterial effect Effects 0.000 description 3
230000008901 benefit Effects 0.000 description 3
229910052794 bromium Inorganic materials 0.000 description 3
229940124630 bronchodilator Drugs 0.000 description 3
239000000168 bronchodilator agent Substances 0.000 description 3
229910052801 chlorine Inorganic materials 0.000 description 3
238000001246 colloidal dispersion Methods 0.000 description 3
239000002131 composite material Substances 0.000 description 3
SNRUBQQJIBEYMU-UHFFFAOYSA-N dodecane Chemical compound CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 3
108010067396 dornase alfa Proteins 0.000 description 3
238000001647 drug administration Methods 0.000 description 3
235000013345 egg yolk Nutrition 0.000 description 3
210000002969 egg yolk Anatomy 0.000 description 3
125000001153 fluoro group Chemical group F* 0.000 description 3
235000021588 free fatty acids Nutrition 0.000 description 3
230000002496 gastric effect Effects 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
229910052740 iodine Inorganic materials 0.000 description 3
239000003120 macrolide antibiotic agent Substances 0.000 description 3
239000000463 material Substances 0.000 description 3
238000005259 measurement Methods 0.000 description 3
229940094933 n-dodecane Drugs 0.000 description 3
230000035515 penetration Effects 0.000 description 3
229960002180 tetracycline Drugs 0.000 description 3
229930101283 tetracycline Natural products 0.000 description 3
235000019364 tetracycline Nutrition 0.000 description 3
150000003522 tetracyclines Chemical class 0.000 description 3
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
ATADHKWKHYVBTJ-FVGYRXGTSA-N (R)-adrenaline hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=C(O)C(O)=C1 ATADHKWKHYVBTJ-FVGYRXGTSA-N 0.000 description 2
108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
BOSAWIQFTJIYIS-UHFFFAOYSA-N 1,1,1-trichloro-2,2,2-trifluoroethane Chemical compound FC(F)(F)C(Cl)(Cl)Cl BOSAWIQFTJIYIS-UHFFFAOYSA-N 0.000 description 2
TWRZCCMKTIMFOF-UHFFFAOYSA-N 1,4-dibromo-1-fluorobutane Chemical compound FC(Br)CCCBr TWRZCCMKTIMFOF-UHFFFAOYSA-N 0.000 description 2
UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
JTYRBFORUCBNHJ-UHFFFAOYSA-N 1-bromo-1,1,2,2,3,3,4,4,5,5,6,6,6-tridecafluorohexane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br JTYRBFORUCBNHJ-UHFFFAOYSA-N 0.000 description 2
SYVYTZLRTMPUCD-UHFFFAOYSA-N 1-chloro-1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Cl SYVYTZLRTMPUCD-UHFFFAOYSA-N 0.000 description 2
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 description 2
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
201000003883 Cystic fibrosis Diseases 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 2
239000004907 Macro-emulsion Substances 0.000 description 2
101710137760 Malonyl-CoA-acyl carrier protein transacylase, mitochondrial Proteins 0.000 description 2
241000187479 Mycobacterium tuberculosis Species 0.000 description 2
102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
208000025865 Ulcer Diseases 0.000 description 2
UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 2
229960003022 amoxicillin Drugs 0.000 description 2
LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 2
230000003698 anagen phase Effects 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
239000002876 beta blocker Substances 0.000 description 2
238000009835 boiling Methods 0.000 description 2
239000012267 brine Substances 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229960002626 clarithromycin Drugs 0.000 description 2
AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
229940127089 cytotoxic agent Drugs 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
238000000151 deposition Methods 0.000 description 2
230000008021 deposition Effects 0.000 description 2
239000003599 detergent Substances 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000002270 dispersing agent Substances 0.000 description 2
239000008151 electrolyte solution Substances 0.000 description 2
239000012634 fragment Substances 0.000 description 2
238000001415 gene therapy Methods 0.000 description 2
NDJKXXJCMXVBJW-UHFFFAOYSA-N heptadecane Chemical compound CCCCCCCCCCCCCCCCC NDJKXXJCMXVBJW-UHFFFAOYSA-N 0.000 description 2
DCAYPVUWAIABOU-UHFFFAOYSA-N hexadecane Chemical compound CCCCCCCCCCCCCCCC DCAYPVUWAIABOU-UHFFFAOYSA-N 0.000 description 2
238000000265 homogenisation Methods 0.000 description 2
230000036571 hydration Effects 0.000 description 2
238000006703 hydration reaction Methods 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
230000006872 improvement Effects 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
150000002634 lipophilic molecules Chemical class 0.000 description 2
229940041033 macrolides Drugs 0.000 description 2
IAIWVQXQOWNYOU-FPYGCLRLSA-N nitrofural Chemical compound NC(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 IAIWVQXQOWNYOU-FPYGCLRLSA-N 0.000 description 2
229960001907 nitrofurazone Drugs 0.000 description 2
125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
230000037361 pathway Effects 0.000 description 2
230000000149 penetrating effect Effects 0.000 description 2
239000013612 plasmid Substances 0.000 description 2
239000002798 polar solvent Substances 0.000 description 2
229920001983 poloxamer Polymers 0.000 description 2
201000000520 progressive familial heart block Diseases 0.000 description 2
229940107568 pulmozyme Drugs 0.000 description 2
238000011002 quantification Methods 0.000 description 2
230000009467 reduction Effects 0.000 description 2
229960002052 salbutamol Drugs 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
239000002904 solvent Substances 0.000 description 2
238000005507 spraying Methods 0.000 description 2
230000006641 stabilisation Effects 0.000 description 2
238000011105 stabilization Methods 0.000 description 2
230000035882 stress Effects 0.000 description 2
238000004114 suspension culture Methods 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
229960000707 tobramycin Drugs 0.000 description 2
NLVFBUXFDBBNBW-PBSUHMDJSA-S tobramycin(5+) Chemical compound [NH3+][C@@H]1C[C@H](O)[C@@H](C[NH3+])O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H]([NH3+])[C@H](O)[C@@H](CO)O2)O)[C@H]([NH3+])C[C@@H]1[NH3+] NLVFBUXFDBBNBW-PBSUHMDJSA-S 0.000 description 2
230000007704 transition Effects 0.000 description 2
231100000397 ulcer Toxicity 0.000 description 2
239000002888 zwitterionic surfactant Substances 0.000 description 2
KBHBUUBXEQUIMV-UHFFFAOYSA-N 1,1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8-heptadecafluorooctane Chemical compound FC(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F KBHBUUBXEQUIMV-UHFFFAOYSA-N 0.000 description 1
AJDIZQLSFPQPEY-UHFFFAOYSA-N 1,1,2-Trichlorotrifluoroethane Chemical compound FC(F)(Cl)C(F)(Cl)Cl AJDIZQLSFPQPEY-UHFFFAOYSA-N 0.000 description 1
SAWCWRKKWROPRB-UHFFFAOYSA-N 1,1-dibromohexane Chemical compound CCCCCC(Br)Br SAWCWRKKWROPRB-UHFFFAOYSA-N 0.000 description 1
FRCHKSNAZZFGCA-UHFFFAOYSA-N 1,1-dichloro-1-fluoroethane Chemical compound CC(F)(Cl)Cl FRCHKSNAZZFGCA-UHFFFAOYSA-N 0.000 description 1
JSEUKVSKOHVLOV-UHFFFAOYSA-N 1,2-dichloro-1,1,2,3,3,3-hexafluoropropane Chemical compound FC(F)(F)C(F)(Cl)C(F)(F)Cl JSEUKVSKOHVLOV-UHFFFAOYSA-N 0.000 description 1
ULTHEAFYOOPTTB-UHFFFAOYSA-N 1,4-dibromobutane Chemical compound BrCCCCBr ULTHEAFYOOPTTB-UHFFFAOYSA-N 0.000 description 1
SGRHVVLXEBNBDV-UHFFFAOYSA-N 1,6-dibromohexane Chemical compound BrCCCCCCBr SGRHVVLXEBNBDV-UHFFFAOYSA-N 0.000 description 1
UOTMYNBWXDUBNX-UHFFFAOYSA-N 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinolin-2-ium;chloride Chemical compound Cl.C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 UOTMYNBWXDUBNX-UHFFFAOYSA-N 0.000 description 1
CVEIKEYTQKDDQK-UHFFFAOYSA-N 1-bromo-1,1,2,2,3,3,4,4,4-nonafluorobutane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)Br CVEIKEYTQKDDQK-UHFFFAOYSA-N 0.000 description 1
VPQQZKWYZYVTMU-UHFFFAOYSA-N 1-bromo-1,1,2,2,3,3,4,4,5,5,6,6,7,7,7-pentadecafluoroheptane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br VPQQZKWYZYVTMU-UHFFFAOYSA-N 0.000 description 1
MNDIARAMWBIKFW-UHFFFAOYSA-N 1-bromohexane Chemical compound CCCCCCBr MNDIARAMWBIKFW-UHFFFAOYSA-N 0.000 description 1
HBXWUCXDUUJDRB-UHFFFAOYSA-N 1-octadecoxyoctadecane Chemical compound CCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCC HBXWUCXDUUJDRB-UHFFFAOYSA-N 0.000 description 1
WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
NEZDNQCXEZDCBI-UHFFFAOYSA-N 2-azaniumylethyl 2,3-di(tetradecanoyloxy)propyl phosphate Chemical compound CCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCC NEZDNQCXEZDCBI-UHFFFAOYSA-N 0.000 description 1
DOSIONJFGDSKCQ-UHFFFAOYSA-N 3-amino-5-pyridin-4-yl-1h-pyridin-2-one;2-hydroxypropanoic acid Chemical compound CC(O)C(O)=O.N1C(=O)C(N)=CC(C=2C=CN=CC=2)=C1 DOSIONJFGDSKCQ-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
229940127291 Calcium channel antagonist Drugs 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
229930186147 Cephalosporin Natural products 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
229910020314 ClBr Inorganic materials 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
102100021906 Cyclin-O Human genes 0.000 description 1
108010053770 Deoxyribonucleases Proteins 0.000 description 1
102000016911 Deoxyribonucleases Human genes 0.000 description 1
MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 1
108010066671 Enalaprilat Proteins 0.000 description 1
101000897441 Homo sapiens Cyclin-O Proteins 0.000 description 1
XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108010083687 Ion Pumps Proteins 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
208000019693 Lung disease Diseases 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
SBKRTALNRRAOJP-BWSIXKJUSA-N N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methylheptanamide (6S)-N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide sulfuric acid Polymers OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O.CC[C@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O SBKRTALNRRAOJP-BWSIXKJUSA-N 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
FELGMEQIXOGIFQ-UHFFFAOYSA-N Ondansetron Chemical compound CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-UHFFFAOYSA-N 0.000 description 1
238000001016 Ostwald ripening Methods 0.000 description 1
229930012538 Paclitaxel Natural products 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
108010093965 Polymyxin B Proteins 0.000 description 1
206010036790 Productive cough Diseases 0.000 description 1
208000002367 Retinal Perforations Diseases 0.000 description 1
GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
239000004147 Sorbitan trioleate Substances 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 description 1
PZQBWGFCGIRLBB-NJYHNNHUSA-N [(2r)-2-[(2s,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1O PZQBWGFCGIRLBB-NJYHNNHUSA-N 0.000 description 1
NVANJYGRGNEULT-BDZGGURLSA-N [(3s,4r,5r)-4-hexadecanoyloxy-5-[(1r)-1-hexadecanoyloxy-2-hydroxyethyl]oxolan-3-yl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@H](CO)[C@H]1OC[C@H](OC(=O)CCCCCCCCCCCCCCC)[C@H]1OC(=O)CCCCCCCCCCCCCCC NVANJYGRGNEULT-BDZGGURLSA-N 0.000 description 1
MKFFGUZYVNDHIH-UHFFFAOYSA-N [2-(3,5-dihydroxyphenyl)-2-hydroxyethyl]-propan-2-ylazanium;sulfate Chemical compound OS(O)(=O)=O.CC(C)NCC(O)C1=CC(O)=CC(O)=C1.CC(C)NCC(O)C1=CC(O)=CC(O)=C1 MKFFGUZYVNDHIH-UHFFFAOYSA-N 0.000 description 1
NIYQLOFJJVVREI-UHFFFAOYSA-N acetic acid;[3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-dodecanoyloxypropyl] dodecanoate Chemical compound CC(O)=O.CCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCC NIYQLOFJJVVREI-UHFFFAOYSA-N 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
229940099424 adenocard Drugs 0.000 description 1
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
229940009456 adriamycin Drugs 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
125000003158 alcohol group Chemical group 0.000 description 1
239000002160 alpha blocker Substances 0.000 description 1
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
230000033115 angiogenesis Effects 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
230000000340 anti-metabolite Effects 0.000 description 1
230000000692 anti-sense effect Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
239000003416 antiarrhythmic agent Substances 0.000 description 1
229940100197 antimetabolite Drugs 0.000 description 1
239000002256 antimetabolite Substances 0.000 description 1
239000003926 antimycobacterial agent Substances 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
229940092705 beclomethasone Drugs 0.000 description 1
229940124748 beta 2 agonist Drugs 0.000 description 1
229940097320 beta blocking agent Drugs 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000008512 biological response Effects 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
150000001621 bismuth Chemical class 0.000 description 1
229920001400 block copolymer Polymers 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
KVWNWTZZBKCOPM-UHFFFAOYSA-M bretylium tosylate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1.CC[N+](C)(C)CC1=CC=CC=C1Br KVWNWTZZBKCOPM-UHFFFAOYSA-M 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229960004436 budesonide Drugs 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000000480 calcium channel blocker Substances 0.000 description 1
229910001424 calcium ion Inorganic materials 0.000 description 1
239000003183 carcinogenic agent Substances 0.000 description 1
229940088029 cardizem Drugs 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
239000003093 cationic surfactant Substances 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
229940124587 cephalosporin Drugs 0.000 description 1
150000001780 cephalosporins Chemical class 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
229940044683 chemotherapy drug Drugs 0.000 description 1
229960005091 chloramphenicol Drugs 0.000 description 1
WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
229940107161 cholesterol Drugs 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
229960001231 choline Drugs 0.000 description 1
210000003040 circulating cell Anatomy 0.000 description 1
239000000084 colloidal system Substances 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
230000002844 continuous effect Effects 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
238000005100 correlation spectroscopy Methods 0.000 description 1
230000000875 corresponding effect Effects 0.000 description 1
239000004064 cosurfactant Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
239000011557 critical solution Substances 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
239000002254 cytotoxic agent Substances 0.000 description 1
231100000599 cytotoxic agent Toxicity 0.000 description 1
230000006378 damage Effects 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
238000002059 diagnostic imaging Methods 0.000 description 1
RNPXCFINMKSQPQ-UHFFFAOYSA-N dicetyl hydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCOP(O)(=O)OCCCCCCCCCCCCCCCC RNPXCFINMKSQPQ-UHFFFAOYSA-N 0.000 description 1
229940093541 dicetylphosphate Drugs 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
HDRXZJPWHTXQRI-BHDTVMLSSA-N diltiazem hydrochloride Chemical compound [Cl-].C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CC[NH+](C)C)C2=CC=CC=C2S1 HDRXZJPWHTXQRI-BHDTVMLSSA-N 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
229960002918 doxorubicin hydrochloride Drugs 0.000 description 1
239000006196 drop Substances 0.000 description 1
238000004070 electrodeposition Methods 0.000 description 1
OYFJQPXVCSSHAI-QFPUQLAESA-N enalapril maleate Chemical compound OC(=O)\C=C/C(O)=O.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 OYFJQPXVCSSHAI-QFPUQLAESA-N 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
229960003072 epinephrine hydrochloride Drugs 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
239000003172 expectorant agent Substances 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000004880 explosion Methods 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
239000003925 fat Substances 0.000 description 1
150000002190 fatty acyls Chemical group 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000010419 fine particle Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
229960000676 flunisolide Drugs 0.000 description 1
229960002714 fluticasone Drugs 0.000 description 1
MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
229960002848 formoterol Drugs 0.000 description 1
BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 1
PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
230000004927 fusion Effects 0.000 description 1
238000007499 fusion processing Methods 0.000 description 1
CHPZKNULDCNCBW-UHFFFAOYSA-N gallium nitrate Inorganic materials [Ga+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O CHPZKNULDCNCBW-UHFFFAOYSA-N 0.000 description 1
229940084478 ganite Drugs 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
ZWCXYZRRTRDGQE-SORVKSEFSA-N gramicidina Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 ZWCXYZRRTRDGQE-SORVKSEFSA-N 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
229940099279 idamycin Drugs 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
150000002460 imidazoles Chemical class 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
239000012678 infectious agent Substances 0.000 description 1
229910017053 inorganic salt Inorganic materials 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000011630 iodine Substances 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
238000002356 laser light scattering Methods 0.000 description 1
239000010410 layer Substances 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
229960002247 lomustine Drugs 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
229910001425 magnesium ion Inorganic materials 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
229940042006 metaproterenol sulfate Drugs 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
DASQOOZCTWOQPA-GXKRWWSZSA-L methotrexate disodium Chemical compound [Na+].[Na+].C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 DASQOOZCTWOQPA-GXKRWWSZSA-L 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
229960004715 morphine sulfate Drugs 0.000 description 1
GRVOTVYEFDAHCL-RTSZDRIGSA-N morphine sulfate pentahydrate Chemical compound O.O.O.O.O.OS(O)(=O)=O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O GRVOTVYEFDAHCL-RTSZDRIGSA-N 0.000 description 1
229940066491 mucolytics Drugs 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
239000002105 nanoparticle Substances 0.000 description 1
239000006199 nebulizer Substances 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
JQEKDNLKIVGXAU-UHFFFAOYSA-L nedocromil sodium Chemical compound [Na+].[Na+].CCN1C(C([O-])=O)=CC(=O)C2=C1C(CCC)=C1OC(C([O-])=O)=CC(=O)C1=C2 JQEKDNLKIVGXAU-UHFFFAOYSA-L 0.000 description 1
239000013642 negative control Substances 0.000 description 1
229940053050 neomycin sulfate Drugs 0.000 description 1
230000009965 odorless effect Effects 0.000 description 1
229940055577 oleyl alcohol Drugs 0.000 description 1
XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
SBQLYHNEIUGQKH-UHFFFAOYSA-N omeprazole Chemical compound N1=C2[CH]C(OC)=CC=C2N=C1S(=O)CC1=NC=C(C)C(OC)=C1C SBQLYHNEIUGQKH-UHFFFAOYSA-N 0.000 description 1
229960000381 omeprazole Drugs 0.000 description 1
239000011022 opal Substances 0.000 description 1
238000000399 optical microscopy Methods 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
239000002357 osmotic agent Substances 0.000 description 1
NVOYVOBDTVTBDX-PMEUIYRNSA-N oxitropium Chemical compound CC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1 NVOYVOBDTVTBDX-PMEUIYRNSA-N 0.000 description 1
229960000797 oxitropium Drugs 0.000 description 1
229960001592 paclitaxel Drugs 0.000 description 1
229960003207 papaverine hydrochloride Drugs 0.000 description 1
230000003071 parasitic effect Effects 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
229940101070 pepto-bismol Drugs 0.000 description 1
239000010702 perfluoropolyether Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
238000005191 phase separation Methods 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
125000005539 phosphatidic acid group Chemical group 0.000 description 1
125000001095 phosphatidyl group Chemical group 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229960003548 polymyxin b sulfate Drugs 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000004088 pulmonary circulation Effects 0.000 description 1
MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
230000005855 radiation Effects 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
208000023504 respiratory system disease Diseases 0.000 description 1
230000004044 response Effects 0.000 description 1
210000001525 retina Anatomy 0.000 description 1
229960004017 salmeterol Drugs 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
150000004756 silanes Chemical class 0.000 description 1
229920002545 silicone oil Polymers 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
210000004872 soft tissue Anatomy 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000005063 solubilization Methods 0.000 description 1
230000007928 solubilization Effects 0.000 description 1
235000019337 sorbitan trioleate Nutrition 0.000 description 1
229960000391 sorbitan trioleate Drugs 0.000 description 1
239000001589 sorbitan tristearate Substances 0.000 description 1
235000011078 sorbitan tristearate Nutrition 0.000 description 1
229960004129 sorbitan tristearate Drugs 0.000 description 1
241000894007 species Species 0.000 description 1
238000002798 spectrophotometry method Methods 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
239000007921 spray Substances 0.000 description 1
210000003802 sputum Anatomy 0.000 description 1
208000024794 sputum Diseases 0.000 description 1
238000003860 storage Methods 0.000 description 1
229960002385 streptomycin sulfate Drugs 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
230000008685 targeting Effects 0.000 description 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
RCINICONZNJXQF-XAZOAEDWSA-N taxol® Chemical compound O([C@@H]1[C@@]2(CC(C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-XAZOAEDWSA-N 0.000 description 1
229940108485 tenormin Drugs 0.000 description 1
238000012360 testing method Methods 0.000 description 1
150000007970 thio esters Chemical class 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
229910052719 titanium Inorganic materials 0.000 description 1
239000010936 titanium Substances 0.000 description 1
238000004448 titration Methods 0.000 description 1
229940108522 trandate Drugs 0.000 description 1
238000002834 transmittance Methods 0.000 description 1
YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
229960002117 triamcinolone acetonide Drugs 0.000 description 1
239000011882 ultra-fine particle Substances 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
230000002792 vascular Effects 0.000 description 1
229940099270 vasotec Drugs 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
239000002569 water oil cream Substances 0.000 description 1
229940072018 zofran Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/113—Multiple emulsions, e.g. oil-in-water-in-oil

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Dispersion Chemistry (AREA)
Hematology (AREA)
Dermatology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Medicinal Preparation (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

KR1019970708834A 1995-06-07 1996-06-05 약물 전달용 역 플루오로카본 유제 조성물 KR19990022354A (ko)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US48761295A	1995-06-07	1995-06-07
US8/487612		1995-06-07

Publications (1)

Publication Number	Publication Date
KR19990022354A true KR19990022354A (ko)	1999-03-25

Family

ID=23936452

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
KR1019970708834A KR19990022354A (ko)	1995-06-07	1996-06-05	약물 전달용 역 플루오로카본 유제 조성물

Country Status (11)

Country	Link
EP (1)	EP0833608A2 (no)
JP (1)	JPH11508237A (no)
KR (1)	KR19990022354A (no)
CN (1)	CN1195981A (no)
AU (1)	AU704918B2 (no)
CA (1)	CA2222063A1 (no)
HU (1)	HUP9900879A2 (no)
IL (1)	IL122249A0 (no)
NO (1)	NO975321L (no)
PL (1)	PL323931A1 (no)
WO (1)	WO1996040057A2 (no)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1999021541A2 (en) *	1997-10-24	1999-05-06	Alliance Pharmaceutical Corp.	Amelioration of ischemic damage using synthetic oxygen carriers
WO1999024016A1 (en) *	1997-11-10	1999-05-20	Sonus Pharmaceuticals, Inc.	Emulsions for aerosolization and drug delivery
US6127430A (en) *	1998-12-16	2000-10-03	3M Innovative Properties Company	Microemulsions containing water and hydrofluroethers
US6159917A (en) *	1998-12-16	2000-12-12	3M Innovative Properties Company	Dry cleaning compositions containing hydrofluoroether
US6312665B1 (en) *	1998-12-21	2001-11-06	Generex Pharmaceuticals Incorporated	Aerosol formulations for buccal and pulmonary application
US7087215B2 (en)	1998-12-21	2006-08-08	Generex Pharmaceuticals Incorporated	Methods of administering and enhancing absorption of pharmaceutical agents
EP1338272A1 (en) *	1998-12-21	2003-08-27	Generex Pharmaceuticals Inc.	Aerosol formulations for buccal and pulmonary application comprising chenodeoxycholate or deoxycholate
US6271200B1 (en)	1998-12-21	2001-08-07	Generex Pharmaceuticals Inc.	Proteinic drug delivery system using aerosolized membrane-mimetic amphiphiles
US6849263B2 (en)	1998-12-21	2005-02-01	Generex Pharmaceutical Incorporated	Pharmaceutical compositions for buccal delivery of pain relief medications
US6294153B1 (en)	1998-12-21	2001-09-25	Generex Pharmaceuticals, Inc.	Aerosol pharmaceutical formulation for pulmonary and nasal delivery
US6451286B1 (en) *	1998-12-21	2002-09-17	Generex Pharmaceuticals Incorporated	Pharmaceutical compositions for buccal and pulmonary administration comprising an alkali metal alkyl sulfate and at least three micelle-forming compounds
US6375975B1 (en) *	1998-12-21	2002-04-23	Generex Pharmaceuticals Incorporated	Pharmaceutical compositions for buccal and pulmonary application
US7357937B2 (en) *	2002-09-24	2008-04-15	Therox, Inc.	Perfluorocarbon emulsions with non-fluorinated surfactants
GB0307403D0 (en) *	2003-03-31	2003-05-07	Medical Res Council	Selection by compartmentalised screening
AU2003903296A0 (en) *	2003-06-30	2003-07-10	Raustech Pty Ltd	Chemical compositions of matter
EP1815869A4 (en) *	2004-11-24	2011-04-06	Nanocarrier Co Ltd	PROCESS FOR CHANGING THE MORPHOLOGY OF BLOCK COPOLYMERS
EP3913375A1 (en)	2006-01-11	2021-11-24	Bio-Rad Laboratories, Inc.	Microfluidic devices and methods of use in the formation and control of nanoreactors
EP2530167A1 (en)	2006-05-11	2012-12-05	Raindance Technologies, Inc.	Microfluidic Devices
US9562837B2 (en)	2006-05-11	2017-02-07	Raindance Technologies, Inc.	Systems for handling microfludic droplets
FR2903602B1 (fr) *	2006-07-12	2012-10-26	Seppic Sa	Formulation injectable a liberation prolongee de principes actifs, procede pour sa preparation
US8772046B2 (en)	2007-02-06	2014-07-08	Brandeis University	Manipulation of fluids and reactions in microfluidic systems
US8592221B2 (en)	2007-04-19	2013-11-26	Brandeis University	Manipulation of fluids, fluid components and reactions in microfluidic systems
AU2009206391A1 (en) *	2008-01-22	2009-07-30	Board Of Regents, The University Of Texas System	Volatile anesthetic compositions and methods of use
EP2123256A1 (en)	2008-05-19	2009-11-25	Ruhr-Universität Bochum	Perfluorcarbon nanoemulsions with endocytosis enhancing surface for gene-transfer
US12038438B2 (en)	2008-07-18	2024-07-16	Bio-Rad Laboratories, Inc.	Enzyme quantification
EP2315629B1 (en)	2008-07-18	2021-12-15	Bio-Rad Laboratories, Inc.	Droplet libraries
US9399797B2 (en)	2010-02-12	2016-07-26	Raindance Technologies, Inc.	Digital analyte analysis
EP4484577A3 (en)	2010-02-12	2025-03-26	Bio-Rad Laboratories, Inc.	Digital analyte analysis
EP2587917A4 (en) *	2010-07-01	2015-05-06	Mtm Res Llc	THERAPIES USING ANTIFIBROBLASTIC FLUOROCHEMICAL EMULSIONS
WO2012003457A1 (en) *	2010-07-01	2012-01-05	Mtm Research Llc	Anti-fibroblastic fluorochemical emulsion therapies
CN103228283A (zh) *	2010-11-29	2013-07-31	千寿制药株式会社	含有二氟泼尼酯和托普霉素的水包油型乳状液组合物
EP3736281A1 (en)	2011-02-18	2020-11-11	Bio-Rad Laboratories, Inc.	Compositions and methods for molecular labeling
CA2830324A1 (en) *	2011-03-31	2012-10-04	Konstanze Schafer	Perfluorinated compounds for non-viral transfer of nucleic acids
DE202012013668U1 (de)	2011-06-02	2019-04-18	Raindance Technologies, Inc.	Enzymquantifizierung
US8658430B2 (en)	2011-07-20	2014-02-25	Raindance Technologies, Inc.	Manipulating droplet size
US11901041B2 (en)	2013-10-04	2024-02-13	Bio-Rad Laboratories, Inc.	Digital analysis of nucleic acid modification
US9944977B2 (en)	2013-12-12	2018-04-17	Raindance Technologies, Inc.	Distinguishing rare variations in a nucleic acid sequence from a sample
WO2015192093A1 (en) *	2014-06-12	2015-12-17	Unger Evan C	Phospholipid composition and microbubbles and emulsions formed using same
US9699301B1 (en) *	2015-05-31	2017-07-04	Emma Michaela Siritzky	Methods, devices and systems supporting driving and studying without distraction
CN109908085B (zh) *	2019-04-23	2021-12-03	董红燕	一种呼吸道给药的药物载体、其制备方法及其在制备治疗心脏病药物中的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2720943B1 (fr) *	1994-06-09	1996-08-23	Applic Transferts Technolo	Emulsions inverses stables à forte concentration en composé(s) fluoré(s) et leur utilisation pour l'administration pulmonaire de médicaments et pour la fabrication d'émulsions multiples.

1996
- 1996-06-05 WO PCT/US1996/009064 patent/WO1996040057A2/en not_active Application Discontinuation
- 1996-06-05 CN CN96195973A patent/CN1195981A/zh active Pending
- 1996-06-05 KR KR1019970708834A patent/KR19990022354A/ko not_active Application Discontinuation
- 1996-06-05 PL PL96323931A patent/PL323931A1/xx unknown
- 1996-06-05 IL IL12224996A patent/IL122249A0/xx unknown
- 1996-06-05 EP EP96919114A patent/EP0833608A2/en not_active Ceased
- 1996-06-05 CA CA002222063A patent/CA2222063A1/en not_active Abandoned
- 1996-06-05 AU AU61537/96A patent/AU704918B2/en not_active Ceased
- 1996-06-05 JP JP9501474A patent/JPH11508237A/ja active Pending
- 1996-06-05 HU HU9900879A patent/HUP9900879A2/hu unknown
1997
- 1997-11-19 NO NO975321A patent/NO975321L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
AU704918B2 (en)	1999-05-06
HU9900879D0 (en)	1999-05-28
JPH11508237A (ja)	1999-07-21
MX9709561A (es)	1998-10-31
PL323931A1 (en)	1998-04-27
HUP9900879A2 (hu)	1999-08-30
NO975321L (no)	1998-01-27
CN1195981A (zh)	1998-10-14
EP0833608A2 (en)	1998-04-08
CA2222063A1 (en)	1996-12-19
NO975321D0 (no)	1997-11-19
IL122249A0 (en)	1998-04-05
AU6153796A (en)	1996-12-30
WO1996040057A3 (en)	1997-02-20
WO1996040057A2 (en)	1996-12-19

Publication	Publication Date	Title
KR19990022354A (ko)	1999-03-25	약물 전달용 역 플루오로카본 유제 조성물
US5980936A (en)	1999-11-09	Multiple emulsions comprising a hydrophobic continuous phase
US5904933A (en)	1999-05-18	Stable reverse and multiple fluorocarbon emulsions
KR100454377B1 (ko)	2005-08-04	약제전달을위한연속플루오로화합물미립분산액
US5733526A (en)	1998-03-31	Hydrocarbon oil/fluorochemical preparations and methods of use
Hippalgaonkar et al.	2010	Injectable lipid emulsions—advancements, opportunities and challenges
FI95439B (fi)	1995-10-31	Menetelmä biologisesti aktiivisten multivesikulaaristen lipidivesikkeleiden tai liposomien valmistamiseksi
PT1545757E (pt)	2007-03-30	Emulsões perfluorcarbonadas com tensioactivos não fluorados
HU229090B1 (en)	2013-07-29	Improvements in or relating to contrast agents
JPH09502700A (ja)	1997-03-18	リポソームの製造方法
EP0514506B1 (en)	1996-05-08	Lipid formulation system
US20130251629A1 (en)	2013-09-26	Nanoemulsion for the delivery of at least two agents of interest
JP2007511545A (ja)	2007-05-10	安定リポソーム組成物
Mehta et al.	2015	Microemulsions: A potential novel drug delivery system
EP0841896B1 (en)	2002-11-13	Reverse gels comprising a continuous fluorinated phase
Chesnoy et al.	2001	Improved DNA/emulsion complex stabilized by poly (ethylene glycol) conjugated phospholipid
MXPA97009561A (es)	1999-01-11	Composiciones de la emulsion de huorocarbobo inverso (privado) para el suministro de medicamento
JP2001515503A (ja)	2001-09-18	軟質粒子、非イオン性界面活性剤および非イオン性曇点調節剤を含む組成物
US10166200B2 (en)	2019-01-01	Buffered oxygen therapeutics
Shah et al.	2015	Surface-active drug loaded lipopolymeric nanohybrid aerosol therapy: potential non-invasive way to mitigate lipopolysaccharide mediated inflammation in murine lungs
CA3152637A1 (en)	2021-03-11	Ophthalmic pharmaceutical composition, preparation methods and uses of same
WO2018124033A1 (ja)	2018-07-05	脂質粒子組成物および医薬組成物
Rosoff	2020	Specialized Pharmaceutical Emulsions
JP2007284395A (ja)	2007-11-01	リポソーム含有製剤の製造方法
WO2024227100A1 (en)	2024-10-31	Nanoparticle composition for oxygen delivery

Legal Events

Date	Code	Title	Description
1997-12-04	PA0105	International application	Patent event date: 19971204 Patent event code: PA01051R01D Comment text: International Patent Application
1999-03-25	PG1501	Laying open of application
2002-03-13	PC1203	Withdrawal of no request for examination
2002-03-13	WITN	Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid